Milan Grkovski1, Shakeel Modak2, Pat B Zanzonico1, Jorge A Carrasquillo3,4, Steven M Larson3,4, John L Humm1, Neeta Pandit-Taskar5,4. 1. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and. 4. Department of Radiology, Weill Cornell Medical College, New York, New York. 5. Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and pandit-n@mkscc.org.
Abstract
The aim of this study was to assess the pharmacokinetics, biodistribution, and radiation dosimetry of 124I-omburtamab administered intraperitoneally in patients with desmoplastic small round cell tumor. Methods: Eligible patients diagnosed with desmoplastic small round cell tumor with peritoneal involvement were enrolled in a phase I trial of intraperitoneal radioimmunotherapy with 131I-omburtamab. After thyroid blockade and before radioimmunotherapy, patients received approximately 74 MBq of 124I-omburtamab intraperitoneally. Five serial PET/CT scans were obtained up to 144 h after injection. Multiple blood samples were obtained up to 120 h after injection. Organ-absorbed doses were calculated with OLINDA/EXM. Results: Thirty-one patients were studied. Blood pharmacokinetics exhibited a biphasic pattern consisting of an initial rising phase with a median half-time (±SD) of 23 ± 15 h and a subsequent falling phase with a median half-time of 56 ± 34 h. Peritoneal distribution was heterogeneous and diffuse in most patients. Self-dose to the peritoneal cavity was 0.58 ± 0.19 mGy/MBq. Systemic distribution and activity in major organs were low. The median absorbed doses were 0.72 ± 0.23 mGy/MBq for liver, 0.48 ± 0.17 mGy/MBq for spleen, and 0.57 ± 0.12 mGy/MBq for kidneys. The mean effective dose was 0.31 ± 0.10 mSv/MBq. Whole-body and peritoneal cavity biologic half-times were 45 ± 9 and 24 ± 5 h, respectively. Conclusion: PET/CT imaging with intraperitoneally administered 124I-omburtamab enables assessment of intraperitoneal distribution and estimation of absorbed dose to peritoneal space and normal organs before therapy.
The aim of this study was to assess the pharmacokinetics, biodistribution, and radiation dosimetry of 124I-omburtamab administered intraperitoneally in patients with desmoplastic small round cell tumor. Methods: Eligible patients diagnosed with desmoplastic small round cell tumor with peritoneal involvement were enrolled in a phase I trial of intraperitoneal radioimmunotherapy with 131I-omburtamab. After thyroid blockade and before radioimmunotherapy, patients received approximately 74 MBq of 124I-omburtamab intraperitoneally. Five serial PET/CT scans were obtained up to 144 h after injection. Multiple blood samples were obtained up to 120 h after injection. Organ-absorbed doses were calculated with OLINDA/EXM. Results: Thirty-one patients were studied. Blood pharmacokinetics exhibited a biphasic pattern consisting of an initial rising phase with a median half-time (±SD) of 23 ± 15 h and a subsequent falling phase with a median half-time of 56 ± 34 h. Peritoneal distribution was heterogeneous and diffuse in most patients. Self-dose to the peritoneal cavity was 0.58 ± 0.19 mGy/MBq. Systemic distribution and activity in major organs were low. The median absorbed doses were 0.72 ± 0.23 mGy/MBq for liver, 0.48 ± 0.17 mGy/MBq for spleen, and 0.57 ± 0.12 mGy/MBq for kidneys. The mean effective dose was 0.31 ± 0.10 mSv/MBq. Whole-body and peritoneal cavity biologic half-times were 45 ± 9 and 24 ± 5 h, respectively. Conclusion: PET/CT imaging with intraperitoneally administered 124I-omburtamab enables assessment of intraperitoneal distribution and estimation of absorbed dose to peritoneal space and normal organs before therapy.
Authors: Jaume Mora; Shakeel Modak; Nai-Kong Cheung; Paul Meyers; Enrique de Alava; Brian Kushner; Heather Magnan; Oscar M Tirado; Michael Laquaglia; Marc Ladanyi; Juan Rosai Journal: Future Oncol Date: 2015 Impact factor: 3.404
Authors: Kim Kramer; Neeta Pandit-Taskar; Pat Zanzonico; Suzanne L Wolden; John L Humm; Carl DeSelm; Mark M Souweidane; Jason S Lewis; Nai-Kong V Cheung Journal: J Neurooncol Date: 2015-05-06 Impact factor: 4.130
Authors: Mark M Souweidane; Kim Kramer; Neeta Pandit-Taskar; Zhiping Zhou; Sofia Haque; Pat Zanzonico; Jorge A Carrasquillo; Serge K Lyashchenko; Sunitha B Thakur; Maria Donzelli; Ryan S Turner; Jason S Lewis; Nai-Kong V Cheung; Steven M Larson; Ira J Dunkel Journal: Lancet Oncol Date: 2018-06-18 Impact factor: 41.316
Authors: Kim Kramer; Brian H Kushner; Shakeel Modak; Neeta Pandit-Taskar; Peter Smith-Jones; Pat Zanzonico; John L Humm; Hong Xu; Suzanne L Wolden; Mark M Souweidane; Steven M Larson; Nai-Kong V Cheung Journal: J Neurooncol Date: 2009-11-05 Impact factor: 4.130